It wasn't so long ago when Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) stocks were flying high thanks to their hotly popular weight loss drugs (Wegovy/Ozempic for Novo Nordisk and ...

The BioWorld Drug Developers Index underperformed both the Nasdaq Biotechnology Index (NBI) and the Dow Jones Industrial Average (DJIA) throughout February and March. However, it showed some recovery ...

The study did not meet its primary endpoint of efficacy against acute gastroenteritis events due to GI.1 or GII.4 norovirus genotypes. No clinical benefit was observed across secondary endpoints.

Drug developer stocks rebounded over July and August, with 23 companies on the BioWorld Drug Developers Index posting gains and only seven declining. The two-month upswing marks a reversal from the ...

Makers of weight-loss drugs, the hottest segment of the pharmaceutical market just now, weren't looking so hot on the stock exchange Tuesday. A pronouncement from President Trump about the category ...

The administration might be launching a campaign specifically targeting such products. This would follow Monday's executive order mandating lower drug prices generally. Makers of weight-loss drugs, ...

A clinical-stage biotech is coming for their lunch. It aims to advance its own weight-loss drug to a phase 3 clinical study in the very near future. In the pharmaceutical industry, as in other sectors ...